FDA advances brigatinib for frontline lung cancer treatment, plus more top stories in hematology/oncology
Brigatinib was granted priority review by the FDA as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. It was the top story in hematology/oncology last week.
Another top story included interim results of the phase 2 TALAPRO-1 study that showed the PARP inhibitor talazoparib (Talzenna, Pfizer Oncology) was active and safe in certain men with metastatic prostate cancer.
Read these and more news in hematology/oncology below:
FDA grants priority review to brigatinib for first-line treatment of ALK-positive lung cancer
The FDA granted priority review to brigatinib as first-line treatment for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, according to the agent’s manufacturer. Read more.
Talazoparib active, safe among subset of men with metastatic prostate cancer
Talazoparib monotherapy induced promising antitumor activity in men with metastatic castration-resistant prostate cancer who previously received docetaxel, according to the first interim analysis of the single-arm, phase 2 TALAPRO-1 study presented at Genitourinary Cancers Symposium. Read more.
FDA committee votes against approval of Tookad for localized prostate cancer
An FDA advisory committee voted 2-13 against recommending approval of padeliporfin di-potassium, a minimally invasive treatment for localized prostate cancer. Read more.
New VTE incidence ‘significant’ after CAR T-cell therapy for lymphoma
More than one in 10 patients with lymphoma who underwent chimeric antigen receptor T-cell therapy developed new venous thromboembolism, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings. Read more.
FDA actions intended to improve safety of laparoscopic power morcellators for gynecologic surgery
The FDA has taken three steps intended to increase the safety of laparoscopic power morcellators when used in gynecologic surgeries, according to a statement released by the agency. Read more.